Heparin-Induced Thrombocytopenia (HIT)

Topic Overview

Summary

Heparin-induced thrombocytopenia (HIT) is a life-threatening, immune-mediated prothrombotic disorder caused by antibodies directed against platelet factor 4 (PF4)-heparin complexes. Despite causing thrombocytopenia, HIT paradoxically leads to a hypercoagulable state with high rates of venous and arterial thrombosis. It typically occurs 5-10 days after heparin exposure and represents a medical emergency requiring immediate cessation of all heparin products and initiation of alternative anticoagulation. [1,2]

The hallmark of HIT is the combination of:

• Thrombocytopenia (platelet drop > 50% from baseline)
• Timing (5-10 days after heparin initiation, or less than 24 hours if recent prior exposure)
• Thrombosis (30-50% of untreated cases)
• Positive anti-PF4/heparin antibodies

Failure to recognize and treat HIT promptly leads to devastating thrombotic complications including limb loss, stroke, myocardial infarction, pulmonary embolism, and death. [3]

Key Facts

• Mechanism: IgG antibodies to PF4-heparin complexes → platelet activation via FcγRIIA receptors → massive thrombin generation → thrombosis + platelet consumption
• Incidence: UFH 1-5%, LMWH 0.1-0.5% (UFH > 10× higher risk)
• Timing: Classic onset 5-10 days; rapid onset (less than 24h) if prior heparin exposure within 100 days; delayed onset (up to 3 weeks after stopping heparin)
• Platelet drop: > 50% fall from baseline (not absolute count); nadir typically 20-150 × 10⁹/L
• Main risk: THROMBOSIS (30-50% untreated), NOT bleeding—this is a prothrombotic state
• Treatment: STOP all heparin immediately + non-heparin anticoagulant (argatroban, fondaparinux, DOAC)
• Critical error: Starting warfarin before platelet recovery → warfarin-induced venous limb gangrene (WILG)
• Mortality: 10-20% if untreated; reduced to 5-10% with appropriate treatment

Clinical Pearls

HIT causes THROMBOSIS despite thrombocytopenia—it is a prothrombotic emergency, not a bleeding disorder

4Ts score: Use to stratify pre-test probability BEFORE ordering laboratory tests—guides management urgency

UFH > LMWH for HIT risk, but LMWH still causes HIT—no heparin product is safe in HIT

NEVER give platelets in HIT—you are "adding fuel to the fire" and may worsen thrombosis

NEVER start warfarin alone or before platelet recovery > 150—risk of catastrophic limb gangrene

Even heparin flushes and heparin-coated catheters can trigger HIT—complete heparin avoidance is mandatory

Why This Matters Clinically

HIT represents one of the most important drug-induced prothrombotic emergencies in medicine. The paradox of thrombocytopenia causing thrombosis (rather than bleeding) makes it clinically counterintuitive and frequently missed. Any patient receiving heparin who develops a platelet drop requires immediate HIT assessment. The window for intervention is narrow—delayed recognition leads to irreversible complications including limb amputation, stroke, and death. Post-cardiac surgery patients, ICU patients, and those on renal replacement therapy are particularly high-risk groups requiring vigilant monitoring. [4,5]

---

Visual Summary

Visual assets to be added:

• HIT pathophysiology diagram (PF4-heparin complex formation, antibody binding, FcγRIIA activation)
• HIT Type I vs Type II comparison table
• 4Ts score calculator
• HIT timing classification (typical, rapid-onset, delayed)
• Laboratory testing algorithm (ELISA → SRA pathway)
• HIT management algorithm (stop heparin → start alternative → transition to warfarin)
• Warfarin-induced limb gangrene mechanism
• Thrombosis distribution chart (venous vs arterial)

---

Epidemiology

Incidence

The incidence of HIT varies dramatically based on heparin type, patient population, and exposure duration: [6,7]

Key Epidemiological Facts:

• UFH causes HIT 10× more frequently than LMWH [8]
• Surgical patients (especially cardiac, orthopaedic) have higher risk than medical patients
• Female sex confers approximately 2× increased risk [9]
• Prophylactic doses and therapeutic doses carry similar risk
• HIT is rare in paediatric patients (antibody formation less common)
• Incidence has declined with increased LMWH use over UFH

Risk Factors

Low Risk Scenarios:

• Medical patients on LMWH: 0.1-0.2%
• Obstetric patients: Very low (pregnancy may be protective)
• Paediatric patients: Rare

Demographics

• Sex: Female > Male (2:1 ratio)
• Age: No strong age predilection in adults; rare in children
• Ethnicity: No significant ethnic variation reported
• Geographic: Worldwide distribution; no regional variation

---

Aetiology & Pathophysiology

Molecular Mechanism

HIT is caused by pathogenic IgG antibodies that recognize complexes of platelet factor 4 (PF4) bound to heparin. The mechanism involves multiple steps: [10,11]

Step 1: PF4-Heparin Complex Formation

1. Heparin administration → circulates in bloodstream
2. PF4 release: Platelet factor 4 (PF4), a positively charged chemokine stored in platelet α-granules, is released from platelets
3. Complex formation: Heparin (negatively charged) binds PF4 (positively charged) → forms ultra-large complexes (ULCs)
4. Conformational change: PF4 undergoes conformational change when bound to heparin, exposing neoepitopes (new antigenic sites)

Why UFH > LMWH?

• UFH has longer polysaccharide chains → forms larger, more immunogenic ULCs
• LMWH has shorter chains → smaller, less immunogenic complexes
• Fondaparinux (pentasaccharide) is too short to form significant ULCs → extremely rare HIT

Step 2: Antibody Formation

• IgG antibody production: Immune system recognizes PF4-heparin ULCs as foreign → generates IgG antibodies (typically IgG1, IgG2)
• Timing: Antibody formation requires 5-10 days (primary immune response)
• Rapid-onset HIT: If prior heparin exposure within 100 days → pre-existing memory B cells → rapid antibody production (less than 24 hours)

Step 3: Platelet Activation (The Thrombotic Cascade)

1. IgG-PF4-heparin immune complexes form
2. Fc portion of IgG binds to FcγRIIA receptors on platelet surface
3. Platelet activation occurs → release of:
   • More PF4 (perpetuating the cycle)
   • Prothrombotic microparticles
   • Thromboxane A2
   • ADP
4. Platelet aggregation → platelet consumption → thrombocytopenia
5. Massive thrombin generation → hypercoagulable state → thrombosis

Step 4: Endothelial Activation

• Antibodies also activate monocytes and endothelial cells
• Tissue factor expression → further thrombin generation
• Endothelial injury → procoagulant surface

Exam Detail: Why Thrombosis Despite Thrombocytopenia? (High-Yield Viva Question)

In HIT, platelets are activated before they are consumed. This is fundamentally different from other causes of thrombocytopenia (e.g., ITP, DIC):

1. Platelet activation → release of prothrombotic microparticles
2. Massive thrombin generation → fibrin formation
3. Endothelial activation → tissue factor expression
4. Monocyte activation → additional procoagulant activity

The thrombocytopenia is a consequence of platelet activation and consumption, but the dominant clinical effect is the hypercoagulable state. Even with platelet counts of 20-40 × 10⁹/L, patients are at high risk of thrombosis, not bleeding.

Exam Answer Template: "HIT is a prothrombotic disorder caused by IgG antibodies to PF4-heparin complexes. These antibodies activate platelets via FcγRIIA receptors, leading to platelet activation, thrombin generation, and thrombosis. The thrombocytopenia results from platelet consumption, but the dominant clinical feature is thrombosis, not bleeding. This paradox occurs because platelets are activated before consumption, releasing prothrombotic microparticles and triggering massive thrombin generation."

HIT Classification

Type I HIT (Non-Immune, Benign)

Type II HIT (Immune-Mediated, Dangerous)

When we refer to "HIT" clinically, we mean Type II (immune-mediated) HIT.

Temporal Classification

---

Clinical Presentation

Thrombocytopenia

Defining Features of HIT Thrombocytopenia: [12]

Common Pitfall:

• Clinicians often wait for "low" platelet counts (less than 50) before considering HIT
• HIT should be suspected with ANY > 50% drop, even if platelets are 100-150 × 10⁹/L
• A drop from 300 → 140 × 10⁹/L is highly suspicious for HIT

Thrombosis (HITT—HIT with Thrombosis)

Thrombotic Manifestations: [13]

Thrombosis occurs in 30-50% of untreated HIT cases. The distribution is:

High-Yield Thrombotic Presentations:

1. Lower limb DVT ± PE (most common)

   • Often bilateral
   • May be extensive (ileofemoral)
   • High risk of progression to PE

2. Limb artery thrombosis

   • Acute limb ischaemia
   • May require thrombectomy or amputation
   • Often occurs in presence of arterial disease

3. Cerebral venous sinus thrombosis

   • Headache, seizures, focal neurology
   • Rare but devastating

4. Bilateral adrenal haemorrhage

   • Adrenal vein thrombosis → haemorrhagic infarction
   • Presents with abdominal pain, hypotension, hyperkalaemia
   • Can mimic septic shock
   • Pathognomonic for HIT when present

5. Skin necrosis at injection sites

   • Due to dermal venous thrombosis
   • Erythematous, painful plaques → necrosis
   • Highly specific for HIT

6. Venous limb gangrene (warfarin-induced)

   • Occurs when warfarin started before platelet recovery
   • Protein C falls before factors II, IX, X → transient hypercoagulability
   • Presents with painful, dusky discolouration of extremities → gangrene
   • Preventable by NOT starting warfarin until platelets > 150

Other Clinical Features

Red Flags for HIT

---

Differential Diagnosis

Causes of Thrombocytopenia in Hospitalized Patients

Exam Detail: Viva Question: How do you distinguish HIT from sepsis-related thrombocytopenia?

Model Answer: "Both HIT and sepsis can cause thrombocytopenia in ICU patients, making differentiation challenging:

Favouring HIT:

• Platelet drop > 50% from baseline (rather than gradual decline)
• Timing 5-10 days after heparin initiation
• Thrombosis (especially venous) rather than bleeding
• Normal coagulation screen (PT, APTT, fibrinogen)
• No evidence of DIC (normal fibrinogen, modest D-dimer elevation)

Favouring sepsis/DIC:

• Multiorgan failure
• Prolonged PT/APTT
• Low fibrinogen (less than 1.5 g/L)
• Markedly elevated D-dimer
• Evidence of bleeding (rather than thrombosis)
• Schistocytes on blood film (DIC/TMA)

Critical point: In the ICU patient on heparin with thrombocytopenia, always calculate a 4Ts score. If intermediate or high probability, treat as HIT (stop heparin, start alternative anticoagulation) while awaiting laboratory confirmation."

---

Clinical Examination

General Examination

• Vital signs: Fever, tachycardia (PE), hypotension (adrenal crisis, PE)
• Level of consciousness: Altered if stroke, cerebral venous thrombosis

Skin Examination

Cardiovascular Examination

Respiratory Examination

• Tachypnoea, hypoxia, pleural rub: Pulmonary embolism

Neurological Examination

• Focal neurological signs: Stroke (arterial thrombosis) or cerebral venous sinus thrombosis
• Headache, papilloedema: Cerebral venous thrombosis

Abdominal Examination

• Loin/flank pain, hypotension: Bilateral adrenal haemorrhage (rare but pathognomonic)
• Acute abdomen: Mesenteric ischaemia (arterial thrombosis)

---

Investigations

Clinical Probability Assessment: 4Ts Score

The 4Ts score is a validated clinical prediction tool used to estimate the pre-test probability of HIT before laboratory testing. It should be calculated in every patient on heparin who develops thrombocytopenia. [14,15]

4Ts Score Criteria

4Ts Score Interpretation

Clinical Application:

• Low 4Ts (0-3): Do NOT send HIT antibody tests (low positive predictive value; false positives common)
• Intermediate 4Ts (4-5): Send ELISA; clinical judgment on whether to stop heparin
• High 4Ts (6-8): Treat as HIT immediately; do NOT wait for laboratory confirmation

Exam Detail: Common Exam Scenario:

"A 65-year-old woman is day 7 post-hip replacement. She has been on LMWH prophylaxis. Baseline platelet count was 250 × 10⁹/L. Today's count is 110 × 10⁹/L. She is otherwise well. What is your approach?"

Model Answer:

"I would calculate the 4Ts score:

• Thrombocytopenia: Platelet fall is 56% (from 250 → 110), nadir 110. Score: 2 points
• Timing: Day 7 post-surgery, consistent with typical-onset HIT. Score: 2 points
• Thrombosis: None reported. Score: 0 points
• Other causes: Possible (post-surgical, haemodilution). Score: 1 point
• Total: 5 points (Intermediate probability)

My management:

1. STOP LMWH immediately
2. Start alternative anticoagulation (e.g., fondaparinux)
3. Send anti-PF4/heparin ELISA
4. Doppler ultrasound lower limbs to exclude DVT
5. Await ELISA result before deciding on duration of anticoagulation"

Laboratory Investigations

Immunological Assays (Antibody Detection)

ELISA Optical Density (OD) Interpretation: [16]

Key Point: Higher OD values correlate with higher likelihood of true HIT. Weakly positive ELISAs (OD 0.4-1.0) have low specificity and often represent false positives.

Functional Assays (Platelet Activation Detection)

SRA Interpretation:

• Positive: Serotonin release with low-dose heparin (0.1 U/mL), inhibited by high-dose heparin (100 U/mL)
• Negative: No serotonin release, or release not inhibited by high heparin

When to Request Functional Assays:

1. Intermediate 4Ts + weakly positive ELISA (OD 0.4-1.0): Functional assay helps confirm or exclude HIT
2. High 4Ts + negative ELISA: Rare; consider functional assay if strong clinical suspicion
3. Medico-legal documentation: SRA provides definitive confirmation

Other Laboratory Tests

Imaging Investigations

Imaging is performed to detect thrombosis, not to diagnose HIT:

---

Management

Immediate Actions: The "HIT Protocol"

When HIT is suspected (intermediate or high 4Ts score), implement the following immediately—do NOT wait for laboratory confirmation: [17,18]

Alternative Anticoagulation Options

First-Line Agents: [19,20]

Direct Oral Anticoagulants (DOACs):

DOACs (rivaroxaban, apixaban, dabigatran, edoxaban) are increasingly used for HIT, particularly in the non-acute phase or stable outpatient setting: [21]

Recommendation: DOACs are acceptable for isolated HIT (no thrombosis) or stable outpatient management. For acute HITT (HIT with thrombosis), start with parenteral agent (argatroban, fondaparinux) initially.

Duration of Anticoagulation

Transition to Warfarin

Warfarin can be used for long-term anticoagulation in HIT, but ONLY after platelet recovery: [22]

Warfarin Transition Protocol:

1. Wait until platelet count > 150 × 10⁹/L
2. Start warfarin at LOW dose (e.g., 5 mg) while continuing alternative anticoagulant
3. Overlap for minimum 5 days AND until INR 2-3 for 2 consecutive days
4. Monitor closely for signs of limb gangrene (pain, dusky discolouration)

Why This Matters:

Warfarin inhibits vitamin K-dependent factors:

• Protein C (half-life 6 hours) falls FIRST → transient hypercoagulable state
• Factor II, IX, X (half-life 24-72 hours) fall later

Starting warfarin before platelet recovery, or without overlapping alternative anticoagulation, causes warfarin-induced venous limb gangrene (WILG):

• Microvascular thrombosis in limb veins
• Painful, dusky discolouration of toes/fingers
• Progresses to gangrene → amputation
• Preventable by following protocol above

Exam Detail: Viva Question: A patient with confirmed HIT has been on fondaparinux for 2 weeks. Platelets have recovered to 200 × 10⁹/L. You plan to switch to warfarin for long-term anticoagulation. How do you do this safely?

Model Answer:

"Warfarin transition in HIT must be done carefully to avoid warfarin-induced venous limb gangrene (WILG):

My approach:

1. Confirm platelet recovery > 150 × 10⁹/L (currently 200—safe to proceed)
2. Start warfarin 5 mg daily (low dose to minimize initial protein C drop)
3. Continue fondaparinux (maintain therapeutic anticoagulation during transition)
4. Check INR daily
5. Overlap for minimum 5 days AND until INR 2-3 on two consecutive days
6. Stop fondaparinux only when INR therapeutic × 2 days
7. Warn patient to report any limb pain or colour change immediately

Mechanism of WILG: Warfarin causes rapid depletion of protein C (half-life 6h) before factors II, IX, X (half-life 24-72h). In HIT, this transient hypercoagulable state, combined with ongoing platelet activation, causes microvascular limb thrombosis → gangrene. Overlapping with a non-warfarin anticoagulant prevents this."

Special Situations

HIT in Pregnancy

• Heparin avoidance: No heparin (UFH or LMWH)
• Fondaparinux: Can be used (does not cross placenta significantly; limited data)
• Danaparoid: Safe in pregnancy (if available)
• DOACs: Contraindicated in pregnancy (teratogenic)
• Warfarin: Teratogenic; avoid in first trimester

HIT in Renal Failure

Recommendation: Argatroban is first-line in severe renal failure (including dialysis).

HIT in Liver Failure

• Argatroban: Dose reduction required (start 0.5 mcg/kg/min)
• Fondaparinux: Safe (no dose adjustment)
• Bivalirudin: Safe
• Warfarin: Baseline elevated INR complicates monitoring

HIT and Cardiac Surgery

Patients with current or recent HIT requiring cardiac surgery face a dilemma: cardiopulmonary bypass (CPB) requires anticoagulation, but heparin is contraindicated.

Options: [23]

Recommendation: If possible, delay cardiac surgery until HIT antibodies clear. If urgent surgery required, use bivalirudin for CPB.

Future Heparin Avoidance

All patients with confirmed HIT must:

1. Carry HIT alert card (medical alert bracelet/card)
2. Documentation in medical record (electronic + paper)
3. Inform all healthcare providers of HIT history
4. Avoid all heparin products in future (UFH, LMWH, heparin flushes)
5. Use fondaparinux or DOACs for VTE prophylaxis if needed

Can heparin EVER be used again?

• Generally NO—avoid all heparin
• Exception: Life-threatening situation (e.g., urgent cardiac surgery) where:
  • No alternative anticoagulant suitable
  • Anti-PF4 antibodies negative (ELISA + SRA)

  • 6 months since HIT episode

  • Short-term use only (single procedure)

---

Complications

Complications of HIT Itself

Complications of Treatment

---

Prognosis & Outcomes

Thrombosis Risk

Mortality

Causes of death:

• Massive pulmonary embolism
• Stroke
• Mesenteric ischaemia
• Multiorgan failure
• Adrenal crisis (bilateral adrenal haemorrhage)

Platelet Recovery

• Time to recovery: Typically 4-10 days after stopping heparin
• Recovery pattern: Platelets rise rapidly once heparin stopped
• Confirms diagnosis: If platelets recover after heparin cessation + positive antibodies → confirms HIT

Long-Term Outcomes

• Antibody clearance: Anti-PF4 antibodies typically clear within 50-100 days (median 50-80 days)
• Recurrence risk: If heparin re-exposed → high risk of recurrent HIT
• Future anticoagulation: Use non-heparin anticoagulants (fondaparinux, DOACs)

---

Evidence & Guidelines

Key Guidelines

1. American Society of Hematology (ASH) 2018 Guidelines on HIT [17]

   • Comprehensive evidence-based recommendations
   • Advocates use of 4Ts score
   • Recommends non-heparin anticoagulants for HIT
   • Conditional recommendation for DOACs in stable patients

2. British Committee for Standards in Haematology (BCSH) 2012 Guidelines [24]

   • UK-focused guidance
   • Emphasizes immediate heparin cessation
   • Laboratory testing algorithm (ELISA first-line)

3. American College of Chest Physicians (ACCP) Antithrombotic Therapy Guidelines [25]

   • Includes HIT management recommendations
   • Evidence-based anticoagulation duration

Key Evidence

Landmark Studies

1. Warkentin et al. (1995): First description of rapid-onset HIT [28]
2. Greinacher et al. (2005): Pathogenesis of HIT—PF4-heparin complexes [10]
3. Cuker et al. (2012): Predictive value of anti-PF4 ELISA optical density [16]

---

Examination Focus

High-Yield Viva Topics

Exam Detail: #### 1. Why does HIT cause thrombosis despite thrombocytopenia?

Model Answer:

"HIT is fundamentally a prothrombotic disorder despite causing thrombocytopenia. The mechanism involves:

Platelet activation before consumption:

• Anti-PF4/heparin antibodies bind FcγRIIA receptors on platelets
• This activates platelets, causing release of prothrombotic microparticles, thromboxane, and ADP
• Platelet activation triggers massive thrombin generation
• The activated platelets are then consumed, causing thrombocytopenia

The thrombocytopenia is a consequence, not the primary pathology. The dominant clinical effect is the hypercoagulable state driven by:

• Platelet-derived microparticles
• Thrombin generation
• Endothelial activation
• Monocyte activation

This is in contrast to other causes of thrombocytopenia (e.g., ITP, bone marrow failure), where platelets are destroyed or not produced, but the remaining platelets function normally. In HIT, the thrombocytopenia reflects ongoing platelet consumption secondary to activation."

2. How do you manage a patient with suspected HIT?

Model Answer:

"My approach follows a structured protocol:

1. Calculate 4Ts score to assess pre-test probability:

• Low (0-3): HIT unlikely; investigate alternatives
• Intermediate (4-5): Send ELISA; consider stopping heparin
• High (6-8): Treat as HIT immediately

2. If intermediate or high 4Ts:

• STOP all heparin (UFH, LMWH, flushes, heparin-coated catheters)
• Do NOT give platelets (may worsen thrombosis)
• Do NOT start warfarin yet (wait until platelets > 150)
• START alternative anticoagulation (argatroban IV or fondaparinux SC)
• Screen for thrombosis (Doppler USS legs, CTPA if indicated)
• Send anti-PF4/heparin ELISA (± SRA if available)

3. Interpret ELISA:

• Negative (less than 0.4): HIT unlikely; consider stopping alternative anticoagulant
• Weakly positive (0.4-1.0): Consider functional assay (SRA)
• Strongly positive (> 1.0): Confirms HIT

4. Duration of anticoagulation:

• Isolated HIT (no thrombosis): 4 weeks
• HIT with thrombosis: 3 months minimum

5. Transition to warfarin (if needed):

• Wait until platelets > 150
• Start low-dose warfarin (5 mg)
• Overlap with alternative anticoagulant for ≥5 days
• Stop alternative anticoagulant only when INR 2-3 × 2 consecutive days

6. Long-term:

• Document HIT in medical record
• HIT alert card/bracelet
• Avoid all heparin in future"

3. What is warfarin-induced venous limb gangrene and how do you prevent it?

Model Answer:

"Warfarin-induced venous limb gangrene (WILG) is a devastating complication seen when warfarin is started in patients with HIT before platelet recovery or without overlapping alternative anticoagulation.

Mechanism: Warfarin inhibits vitamin K-dependent clotting factors. Protein C (anticoagulant; half-life 6 hours) falls rapidly, BEFORE factors II, IX, X (procoagulant; half-life 24-72 hours) fall. This creates a transient hypercoagulable state. In HIT, where there is already ongoing platelet activation and thrombin generation, this transient hypercoagulability causes microvascular thrombosis in limb veins → venous gangrene.

Presentation:

• Painful, dusky discolouration of toes/fingers
• Progresses to necrosis and gangrene
• Requires amputation in severe cases

Prevention:

1. NEVER start warfarin until platelets > 150 × 10⁹/L
2. Start warfarin at LOW dose (e.g., 5 mg)
3. Overlap with alternative anticoagulant (argatroban, fondaparinux) for minimum 5 days
4. Ensure INR 2-3 for 2 consecutive days before stopping alternative anticoagulant
5. Monitor closely for limb pain or colour change

This is entirely preventable by following the above protocol."

4. When can heparin be used again after HIT?

Model Answer:

"The general rule is: NEVER use heparin again after confirmed HIT.

However, there are rare exceptions in life-threatening situations:

Heparin may be considered if ALL of the following are met:

1. Life-threatening situation requiring anticoagulation with no suitable alternative (e.g., urgent cardiac surgery requiring cardiopulmonary bypass)
2. > 6 months since HIT episode
3. Anti-PF4 antibodies negative (both ELISA and SRA)
4. Short-term use only (single procedure, not ongoing therapy)
5. Close monitoring for platelet drop

If antibodies are still positive, heparin is CONTRAINDICATED even in emergencies. Alternatives:

• Bivalirudin for cardiac surgery/CPB
• Fondaparinux for VTE prophylaxis/treatment
• DOACs for long-term anticoagulation

For routine situations:

• Use fondaparinux or DOACs for VTE prophylaxis
• Use DOACs for atrial fibrillation
• Avoid all heparin products indefinitely"

5. How do you interpret anti-PF4 ELISA results?

Model Answer:

"Anti-PF4/heparin ELISA detects antibodies to PF4-heparin complexes. The result is reported as an optical density (OD) value.

Interpretation:

Key principles:

1. Higher OD → higher likelihood of true HIT
2. Weakly positive results (0.4-1.0) often false positives—these patients may have non-pathogenic antibodies
3. ELISA alone does not confirm HIT—must correlate with clinical context (4Ts score)
4. Functional assay (SRA) is gold standard—detects only pathogenic antibodies that activate platelets

Example:

• High 4Ts score (7) + strongly positive ELISA (OD 2.5) → HIT confirmed
• Low 4Ts score (2) + weakly positive ELISA (OD 0.6) → HIT unlikely; false positive ELISA

Bottom line: ELISA is a screening test. Strongly positive results in appropriate clinical context confirm HIT. Weakly positive results require further evaluation (SRA) or clinical judgment."

Common Exam Scenarios

Scenario 1: Post-Cardiac Surgery Thrombocytopenia

"A 70-year-old man is day 6 post-CABG. He received UFH perioperatively and has been on LMWH prophylaxis postoperatively. Baseline platelet count was 300 × 10⁹/L. Today's count is 120 × 10⁹/L. What is your differential diagnosis and management?"

Key Points:

• High-risk for HIT (cardiac surgery, UFH exposure)
• Platelet drop = 60% (from 300 → 120)
• Timing = day 6 (classic for HIT)
• Calculate 4Ts score (likely high probability)
• Stop LMWH, start alternative anticoagulation, send ELISA

Scenario 2: Acute Limb Ischaemia on Heparin

"A 65-year-old woman with AF is on therapeutic LMWH following a PE. Day 8, she develops acute right leg ischaemia. Platelet count has dropped from 250 → 90 × 10⁹/L. What is your diagnosis and immediate management?"

Key Points:

• HIT with arterial thrombosis (HITT)
• Stop LMWH immediately
• Start argatroban (IV for rapid effect)
• Vascular surgery consult (thrombectomy vs amputation)
• Send anti-PF4 ELISA
• Do NOT give warfarin until platelets recover

Scenario 3: Thrombocytopenia in ICU

"An ICU patient on UFH infusion for PE develops thrombocytopenia (300 → 120 × 10⁹/L) on day 7. The patient has sepsis and multiorgan failure. How do you differentiate HIT from sepsis-related thrombocytopenia?"

Key Points:

• Calculate 4Ts score
• Check coagulation (PT, APTT, fibrinogen)—normal in HIT, abnormal in DIC
• Look for thrombosis (favours HIT) vs bleeding (favours DIC/sepsis)
• If intermediate/high 4Ts, treat as HIT while awaiting results

---

Patient & Family Information

What is HIT?

Heparin-induced thrombocytopenia (HIT) is a serious reaction to heparin, a blood-thinning medication. Your immune system makes antibodies against heparin when it binds to a protein in your blood called platelet factor 4 (PF4). These antibodies activate your platelets (blood clotting cells), which paradoxically increases your risk of blood clots.

Why is it Serious?

HIT causes low platelet counts but high clot risk. This is unusual—most conditions with low platelets cause bleeding, but HIT causes clotting. Blood clots can form in:

• Legs (deep vein thrombosis)
• Lungs (pulmonary embolism)
• Arteries (causing stroke, heart attack, or limb ischaemia)

Without treatment, up to half of people with HIT develop dangerous blood clots.

What Are the Symptoms?

• New blood clot (leg swelling, chest pain, shortness of breath)
• Skin reactions at heparin injection sites (redness, pain, blistering)
• Drop in platelet count (detected on blood tests)

Most people have no symptoms—HIT is detected on routine blood tests.

How is HIT Treated?

Immediate steps:

1. Stop all heparin (injections, IV drips, line flushes)
2. Start a different blood thinner (not heparin-based)—options include:
   • Argatroban (given through IV drip)
   • Fondaparinux (injection once daily)
   • Rivaroxaban or apixaban (tablets)
3. Monitor platelets until they recover
4. Check for blood clots (ultrasound scans)

Duration: You will need blood thinners for at least 4 weeks (if no clot) or 3 months (if clot developed).

What Happens Next?

• Your platelet count will recover within days to weeks after stopping heparin
• You must avoid all heparin in the future (UFH, LMWH, heparin flushes)
• You should carry a HIT alert card or medical alert bracelet
• Inform all doctors, nurses, and dentists about your HIT history

Can I Ever Have Heparin Again?

No, you should avoid heparin for life. There are alternative blood thinners available for any situation:

• For blood clot prevention: Fondaparinux injections or tablets (rivaroxaban, apixaban)
• For surgery: Fondaparinux or other non-heparin blood thinners
• For heart procedures: Bivalirudin (heparin alternative)

What if I Need Surgery?

Tell your surgeon and anaesthetist about your HIT history. They will use alternative blood thinners instead of heparin.

Resources

• Thrombosis UK — Information on blood clots
• NHS Blood Clots — Patient information
• HIT Support Group — Patient support and education

---

References

Primary Guidelines

1. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392. doi:10.1182/bloodadvances.2018024489 PMID: 30482768

2. Watson H, Davidson S, Keeling D; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol. 2012;159(5):528-540. doi:10.1111/bjh.12059 PMID: 23043677

Key Reviews

3. Arepally GM. Heparin-induced thrombocytopenia. Blood. 2017;129(21):2864-2872. doi:10.1182/blood-2016-11-709873 PMID: 28416506

4. Greinacher A. Heparin-induced thrombocytopenia. N Engl J Med. 2015;373(3):252-261. doi:10.1056/NEJMcp1411910 PMID: 26176382

5. Salter BS, Weiner MM, Trinh MA, et al. Heparin-induced thrombocytopenia: a comprehensive clinical review. J Am Coll Cardiol. 2016;67(21):2519-2532. doi:10.1016/j.jacc.2016.02.073 PMID: 27230050

Epidemiology

6. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8):2710-2715. doi:10.1182/blood-2005-04-1546 PMID: 15985543

7. Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96(5):1703-1708. PMID: 10961866

8. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003;101(8):2955-2959. doi:10.1182/blood-2002-07-2201 PMID: 12480715

9. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330-1335. doi:10.1056/NEJM199505183322003 PMID: 7715641

Pathophysiology

10. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost. 2005;94(1):132-135. doi:10.1160/TH04-12-0825 PMID: 16113796

11. Cines DB, Rauova L, Arepally G, et al. Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J Clin Apher. 2007;22(1):31-36. doi:10.1002/jca.20117 PMID: 17167778

Clinical Features

12. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344(17):1286-1292. doi:10.1056/NEJM200104263441704 PMID: 11320389

13. Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999;106(6):629-635. doi:10.1016/s0002-9343(99)00124-2 PMID: 10378619

Diagnosis

14. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759-765. doi:10.1111/j.1538-7836.2006.01787.x PMID: 16634744

15. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120(20):4160-4167. doi:10.1182/blood-2012-07-443051 PMID: 22990018

16. Cuker A, Rux AH, Hinds JL, et al. Novel diagnostic assays for heparin-induced thrombocytopenia. Blood. 2013;121(18):3727-3732. doi:10.1182/blood-2012-09-454280 PMID: 23446735

Management

17. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e495S-e530S. doi:10.1378/chest.11-2303 PMID: 22315270

18. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):340S-380S. doi:10.1378/chest.08-0677 PMID: 18574270

19. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103(14):1838-1843. doi:10.1161/01.cir.103.14.1838 PMID: 11294800

20. Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost. 2008;99(1):208-214. doi:10.1160/TH07-04-0252 PMID: 18217158

21. Sharifi M, Bay C, Vajo Z, et al. New oral anticoagulants in the treatment of heparin-induced thrombocytopenia. Thromb Res. 2015;135(4):607-609. doi:10.1016/j.thromres.2015.01.009 PMID: 25634779

Complications

22. Warkentin TE, Elavathil LJ, Hayward CP, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127(9):804-812. doi:10.7326/0003-4819-127-9-199711010-00005 PMID: 9382401

23. Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg. 2007;83(2):572-577. doi:10.1016/j.athoracsur.2006.09.038 PMID: 17257992

Prognosis

24. Warkentin TE. HIT paradigms and paradoxes. J Thromb Haemost. 2011;9 Suppl 1:105-117. doi:10.1111/j.1538-7836.2011.04322.x PMID: 21781246

25. Linkins LA, Bates SM, Lee AY, et al. Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. Blood. 2015;126(5):597-603. doi:10.1182/blood-2014-12-618165 PMID: 26045607

Historical Landmark Studies

26. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163(15):1849-1856. doi:10.1001/archinte.163.15.1849 PMID: 12912723

27. Kang M, Alahmadi M, Sawh S, et al. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood. 2015;125(6):924-929. doi:10.1182/blood-2014-09-599498 PMID: 25498911

28. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502-507. doi:10.1016/s0002-9343(96)00258-6 PMID: 8948273

---